ATROVENT HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ATROVENT HFA (ATROVENT HFA).
Antagonist of muscarinic acetylcholine receptors (M1-M3), blocking acetylcholine-mediated bronchoconstriction and mucus secretion in airways.
| Metabolism | Partially metabolized via hydrolysis to inactive metabolites; minor involvement of cytochrome P450 enzymes (CYP2D6, CYP3A4). |
| Excretion | Renal (70% as unchanged drug and metabolites), fecal (20% as metabolites, primarily via biliary excretion). |
| Half-life | Terminal elimination half-life is approximately 1.5 hours. Clinically, bronchodilation persists longer due to local retention in the airways. |
| Protein binding | 20–40% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 2.5 L/kg (extensive distribution into tissues, consistent with a quaternary ammonium compound with limited CNS penetration). |
| Bioavailability | Inhalation: ~10% (systemic absorption from lung and gastrointestinal tract; majority of dose remains in the lung or is swallowed). |
| Onset of Action | Inhalation: 15–30 minutes for significant bronchodilation. |
| Duration of Action | Inhalation: 3–5 hours (bronchodilation lasts 4–6 hours with some variation; dosing every 6 hours recommended). |
| Molecular Weight | 430.37 |
| Action Class | Anticholinergic Bronchodilator |
2 inhalations (34 mcg per inhalation) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children (≥5 years): 1-2 inhalations (34 mcg per inhalation) three to four times daily via oral inhalation; maximum 8 inhalations in 24 hours. For children <5 years, use is not recommended. |
| Geriatric use | Elderly patients: No specific dosage adjustment; use with caution due to potential anticholinergic effects and comorbid conditions. Initiate at lower end of dosing range if necessary. |
| 1st trimester | Limited data; no evidence of teratogenicity in animal studies. Use only if clearly needed and potential benefit justifies risk. |
| 2nd trimester | No known fetal risk; consider use if benefit outweighs risk. |
| 3rd trimester | No known fetal risk; may cause maternal tachycardia. Use if needed. |
Clinical note
Comprehensive clinical and safety monograph for ATROVENT HFA (ATROVENT HFA).
| Placental transfer | Minimal placental transfer due to quaternary ammonium structure and low lipid solubility. |
| Breastfeeding | Ipratropium bromide is excreted in breast milk in very small amounts; not expected to cause adverse effects in nursing infants due to poor oral bioavailability. |
| Lactation Rating |
■ FDA Black Box Warning
Not indicated for acute episodes of bronchospasm; no black box warning.
| Common Effects | Cough, Dry mouth, Headache, Dizziness, Nausea, Pharyngitis, Upper respiratory tract infection |
| Serious Effects | Paradoxical bronchospasm, Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, anaphylaxis), Worsening of narrow-angle glaucoma (if sprayed into eyes), Urinary retention (especially in patients with prostatic hyperplasia or bladder-neck obstruction) |
Hypersensitivity to atropine or its derivativesHypersensitivity to ipratropium bromide or any component of the product
| Precautions | Not for acute bronchospasm; may cause paradoxical bronchospasm; caution in narrow-angle glaucoma, prostatic hyperplasia, and bladder neck obstruction; immediate hypersensitivity reactions reported. |
| Food/Dietary |
Loading safety data…
| L1 (Safe) |
| Teratogenic Risk | Pregnancy Category B. Animal studies show no teratogenic effects. No adequate human studies in first trimester; however, inhaled ipratropium has minimal systemic absorption, suggesting low fetal risk. Use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required; standard prenatal care. Monitor for maternal bronchodilator efficacy and potential systemic anticholinergic effects (rare). |
| Fertility Effects | No known impairment of fertility in animal studies. Human data insufficient; no anticipated impact on fertility due to minimal systemic absorption. |
| No known food interactions with ipratropium bromide. No dietary restrictions required. |
| Clinical Pearls | ATROVENT HFA (ipratropium bromide) is an anticholinergic bronchodilator used for maintenance treatment of COPD, including chronic bronchitis and emphysema. It is not indicated for acute episodes or for asthma. Onset of action is 15-30 minutes, peak effect at 1-2 hours, duration 3-4 hours. Administer via HFA inhaler; patients should prime with 2 test sprays before first use or if not used for more than 3 days. Shake well before each use. Do not exceed 4 inhalations per day (2 inhalations 4 times daily). |
| Patient Advice | Use exactly as prescribed; do not increase dose or frequency. · Rinse mouth after use to reduce risk of dry mouth and throat irritation. · Report worsening symptoms, eye pain, blurred vision, or difficulty urinating. · Avoid getting spray in eyes; may cause temporary blurred vision or eye pain. · Store at room temperature away from heat and flame; do not puncture or burn canister. |